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Abstract
Targeted immune-modulating agents are entering clini-
cal practice in many specialties, providing novel thera-
peutic possibilities but introducing new potential toxici-
ties. We present the first reported case, to our knowledge,
of immune-mediated nephritis following the administra-
tion of Tremelimumab (CP-675, 206), an anti-cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal
antibody. High-dose steroid therapy led to a rapid improve-
ment in renal function, avoiding the need for renal replace-
ment therapy.
Keywords: acute renal impairment; CTLA-4 antibody; interstitial
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Case report
A 41-year-old man with Stage IV malignant melanoma
(MM) was referred to the renal services with acute renal
impairment. His initial disease had been surgically man-
aged several months previously, but a follow-up surveil-
lance computed tomography (CT) scan demonstrated
multiple metastases with intra-abdominal and retroperi-
toneal lymphadenopathy. He was, therefore, enrolled into
a phase III clinical trial of an immune activating anti-
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
antibody.
At enrolment, his serum creatinine was 98 μmol/L
[eGFR 78 mL/min/1.73 m2 (MDRD 4)], and he received a
total dose of 1280 mg (15 mg/kg) anti-CTLA-4 antibody
(Tremelimumab, CP-675, 206, Pfizer, Boehringer Ingel-
heim Pharma KG). One week later, he developed lethargy,
nausea and vomiting. Blood tests revealed acute renal fail-
ure, with a serum creatinine 208 μmol/L, which over the
next week rose to 544 μmol/L. Urinalysis showed a trace
of blood but no red cell casts on microscopy. An ultrasound
scan demonstrated unobstructed, normal-sized kidneys. An
autoimmune screen revealed positive antinuclear antibody
(ANA) to a titre of 1:320 (fine-speckled pattern), but nega-
tive double stranded DNA (dsDNA) and extractable nuclear
antigen (ENA). Complement levels and immunoglobulins
were normal. Anti-cardiolipin antibodies were negative,
as were anti-neutrophil cytoplasmic antibody (ANCA),
glomerular basement membrane antibody (GBM) and an
autoimmune liver disease screen.
Examination showed that he was euvolaemic, hyper-
tensive (165/90 mmHg) and had vitiligo. A subsequent
renal biopsy (Figure 1) demonstrated an active inflam-
matory interstitial infiltrate. Stains for melanoma cells,
S100, Melan-A and HMB45, were negative. Both electron
microscopy and immunofluorescence excluded immune-
complex glomerulonephritis. Further stains identified the
major infiltrating cell type as CD8+ T-lymphocytes. Hewas
commenced on high-dose oral prednisolone (60 mg/day).
Within 2 weeks, his creatinine had fallen to 195 μmol/L
but then plateaued. A magnetic resonance urogram (MRU)
confirmed the presence of large volume metastases in the
retroperitoneum, abdomen and pelvis with consequent bi-
lateral hydronephrosis and hydroureter. In the hope of pre-
ventingworsening ureteric obstruction in the face of disease
progression, he was referred for bilateral ureteric stenting.
The serum creatinine fell to 114 μmol/L, and prednisolone
therapy was consequently weaned (Figure 2). He subse-
quently received dacarbazine chemotherapy but sadly died
from irreversible disease progression a few months later.
Discussion
Biological agents that target specific elements of the im-
mune response are increasingly used in the treatment of
autoimmune diseases and cancers, including MM. MM is
increasing in incidence in the UK [1], and patients with ad-
vanced disease have a poor response to conventional treat-
ment. Immunotherapy inMMis aimed at breaking tolerance
to tumour-specific self-antigen, thus facilitating clearance
of cancer cells by the patient’s own immune system. Treat-
ments trialled include those stimulating generalized effec-
tor T cell activation, such as recombinant interferon alpha
(IFN-α) and interleukin-2 (IL-2) [2], and those aimed at
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Fig. 1. (A) Native renal biopsy showing an active inflammatory infiltrate in the interstitium (arrow) (H+E). (B) Immunohistochemical preparation for
pan-T cell marker CD3. (C) CD4 staining. (D) CD8 staining.
promoting a tumour-specific immune response, for exam-
ple vaccination with a tumour antigen [3] or with tumour
antigen-loaded dendritic cells [4].
CTLA-4 (CD 152) is a molecule expressed on T cells fol-
lowing activation and provides an internal mechanism by
which T cells can limit or terminate an immune response.
Blockade of CTLA-4 with an antagonist monoclonal anti-
body such as Tremelimumab (CP-675, 206) promotes T cell
activation [5] and inhibits themaintenance of self-tolerance.
However, this loss of self-tolerance is not tumour specific
and can lead to the development of a variety of autoimmune
diseases, termed immune-related adverse events (IRAEs).
Other strategies promoting generalized effector T cell acti-
vation such as the administration of IFN-α and IL-2 are also
associated with the development of autoimmunity [6,7].
Two humanized CTLA-4 monoclonal antibodies—
Ipilimumab/MDX-010 (Medarex, Bristol-Myers Squibb)
and Tremelimumab (CP-675, 206) (Pfizer)—are in clinical
development for the treatment of a variety of malignancies
including MM, renal cell, ovarian and colonic carcinoma.
Phase III data are awaited for both drugs. Ipilimumab has
been shown to induce a clinical response in a small minority
of patients, but its use is associated with the development of
a number of autoimmune phenomena including dermatitis,
enterocolitis, hypophysitis and one case of nephritis [8–10].
Enterocolitis is the most common IRAE observed affecting
up to 20% of patients, and results in significant morbidity
and mortality (four bowel perforations, one colectomy and
two deaths [10]). High-dose steroid therapy settled symp-
toms in the majority of patients, without objectively re-
ducing treatment response. Interestingly, objective tumour
regression was associated with the occurrence of entero-
colitis, emphasising the non-specific nature of the break in
self-tolerance achieved through use of CTLA-4 antagonist
antibodies.
The antibody our patient received (Tremelimumab, CP-
675, 206), whilst demonstrating anti-tumour activity in a
phase I clinical trial, also resulted in the development of
autoimmune disease [11] (including enterocolitis, dermati-
tis, vitiligo, panhypopituitarism and autoimmune thyroid
disease).
The patient we have described developed vitiligo, nephri-
tis and detectable levels of ANA, presumably secondary to
Tremelimumab (CP-675, 206) associated immune dysreg-
ulation. The temporal relationship between drug adminis-
tration and presentation would support this theory, as would
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Fig. 2. Serum creatinine and response to treatment with A—
corticosteroids and B—ureteric stents.
the T lymphocytic inflammatory infiltrate on renal biopsy,
and prompt response to steroid therapy. The nephritis ob-
served by Beck et al. [10] (personal communication) in one
of their patients treatedwith Ipilimumab followed an almost
identical clinical course to the one we observed (acute renal
insufficiency, bland urinary sediment, interstitial nephritis
on renal biopsy and prompt response to high-dose steroids).
Furthermore, other groups have reported similar histolog-
ical findings in skin [9,11], bowel [9,10] and liver [12]
biopsies from patients displaying presumed autoimmune
toxicity following anti CTLA-4 therapy.
It is difficult to determine whether the lymphocytic in-
terstitial infiltrate observed in our patient was secondary
to an immune reaction to drug antigens or a drug-induced
loss of tolerance to self-antigens. The latter theory would
fit with the additional clinical findings of positive ANA and
vitiligo. Regardless of the mechanism of immune dysregu-
lation, however, early intervention with high-dose steroids
has proven efficacious in patients experiencing other organ-
threatening significant IRAEs [12].
Although the routine use of steroids in drug-induced in-
terstitial nephritis is controversial, there is a growing body
of evidence to suggest that early intervention with steroids
after the culprit drug(s) has been discontinued helps to min-
imize the risk of interstitial fibrosis and permanent renal
insufficiency [13]. If, as is more likely, the nephritis was
autoimmune in nature, the benefit of steroid therapy is clear-
cut with the wealth of literature surrounding the treatment
of systemic lupus erythematosus (SLE), particularly lupus
nephritis [14], supporting such a therapeutic approach.
One final learning point from this case was the de-
tection of an additional pathology. After an initial en-
couraging response to steroids, our patient’s renal func-
tion plateaued at a higher baseline, despite prompt steroid
treatment. At this stage, an alternative pathologywas sought
and, indeed, obstructive uropathy secondary to tumour bur-
den was identified. An improvement in serum creatinine to
original baseline was achieved with bilateral ureteric stent-
ing, facilitating further chemotherapy administration in the
form of dacarbazine.
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